The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trial
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, shares some insights into the BRUIN CLL-321 study (NCT04666038), evaluating the use of pirtobrutinib versus investigator’s choice for the treatment of chronic lymphocytic leukemia (CLL). Prof. Jurczak highlights the importance of Bruton’s tyrosine kinase (BTK) inhibitors in CLL treatment and the impressive tolerability and low toxicity of pirtobrutinib compared to other agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
